Immune Design Corp Company Profile (NASDAQ:IMDZ)

About Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp logoImmune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IMDZ
  • CUSIP: N/A
  • Web: www.immunedesign.com
Capitalization:
  • Market Cap: $204.57 million
  • Outstanding Shares: 25,571,000
Average Prices:
  • 50 Day Moving Avg: $6.44
  • 200 Day Moving Avg: $6.38
  • 52 Week Range: $4.50 - $13.43
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.86
  • P/E Growth: -0.70
Sales & Book Value:
  • Annual Revenue: $16.86 million
  • Price / Sales: 12.13
  • Book Value: $3.33 per share
  • Price / Book: 2.40
Profitability:
  • EBIDTA: ($48,160,000.00)
  • Net Margins: -415.05%
  • Return on Equity: -50.92%
  • Return on Assets: -46.08%
Debt:
  • Current Ratio: 7.33%
  • Quick Ratio: 7.29%
Misc:
  • Average Volume: 95,771 shs.
  • Beta: 3.01
  • Short Ratio: 7.46
 

Frequently Asked Questions for Immune Design Corp (NASDAQ:IMDZ)

What is Immune Design Corp's stock symbol?

Immune Design Corp trades on the NASDAQ under the ticker symbol "IMDZ."

How were Immune Design Corp's earnings last quarter?

Immune Design Corp (NASDAQ:IMDZ) announced its quarterly earnings results on Tuesday, March, 7th. The company reported ($0.57) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.57). The business had revenue of $2.06 million for the quarter, compared to analysts' expectations of $1.34 million. Immune Design Corp had a negative net margin of 415.05% and a negative return on equity of 50.92%. View Immune Design Corp's Earnings History.

Where is Immune Design Corp's stock going? Where will Immune Design Corp's stock price be in 2017?

3 analysts have issued 1 year price targets for Immune Design Corp's shares. Their predictions range from $18.00 to $18.00. On average, they anticipate Immune Design Corp's share price to reach $18.00 in the next year. View Analyst Ratings for Immune Design Corp.

What are analysts saying about Immune Design Corp stock?

Here are some recent quotes from research analysts about Immune Design Corp stock:

  • 1. According to Zacks Investment Research, "Immune Design’s primary candidates, CMB305 and G100, are being evaluated for solid tumor, and merkel cell carcinoma (MCC) and sarcoma, respectively. Immune Design has a number of candidates in its pipeline but none is in late-stage development and consequently several years away from commercialization. An unfavorable result from any of the studies may force the company to postpone or discontinue the studies. The company is highly dependent on its collaboration partners for top-line growth which increases its vulnerability. The company’s shares have underperformed the Medical-Drugs industry year to date. Loss estimates have widened lately ahead of the Q1 earnings results. However, the company expects to provide significant clinical data produced by both lead product candidate in both monotherapy and in combination trials to support their potential registration paths towards commercialization in 2017." (5/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Though 2016 was relatively quiet, we believe the year of trial execution helped establish a foundation to build upon in 2017, with accumulating CMB305/ LV305 OS data and randomized '305 and '100 datasets potentially helping confirm the agents' promise and potential regulatory path. With data at AACR, ASCO, ESMO, and ASH this year, we see catalysts to draw greater attention to IMDZ and drive upside for shares; increasing tgt to $16. Financials: 4Q OpEx was $16.6M, consisting of $12.0M R&D vs. our $11.6M est and $4.4M G&A, vs. our $4.2M est. Their net loss was $14.5M compared to our $13.8M est. The company ended the quarter with $110.4M in cash, which includes $30.3M from follow-on financing. IMDZ believes their cash position should provide a runway until 2H18. Updated follow-up data for CMB305 and LV305 in soft tissue sarcoma (STS) suggests survival tracking well ahead of historical data." (3/8/2017)

Who are some of Immune Design Corp's key competitors?

Who owns Immune Design Corp stock?

Immune Design Corp's stock is owned by many different of institutional and retail investors. Top institutional investors include Versant Venture Management LLC (8.68%), ProQuest Associates IV LLC (7.68%), Victory Capital Management Inc. (7.62%), FMR LLC (1.75%), Vanguard Group Inc. (1.50%) and JPMorgan Chase & Co. (0.95%). Company insiders that own Immune Design Corp stock include Carlos V Paya, Franklin M Berger, Group L P Column, Lewis W Coleman, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design Corp.

Who sold Immune Design Corp stock? Who is selling Immune Design Corp stock?

Immune Design Corp's stock was sold by a variety of institutional investors in the last quarter, including Weiss Multi Strategy Advisers LLC, JPMorgan Chase & Co., Morgan Stanley, Oxford Asset Management and Bank of New York Mellon Corp. Company insiders that have sold Immune Design Corp stock in the last year include Carlos V Paya, Franklin M Berger, Lewis W Coleman and Stephen R Brady. View Insider Buying and Selling for Immune Design Corp.

Who bought Immune Design Corp stock? Who is buying Immune Design Corp stock?

Immune Design Corp's stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Renaissance Technologies LLC, Vanguard Group Inc., Wells Fargo & Company MN, Trexquant Investment LP, Dimensional Fund Advisors LP, Bank of America Corp DE and TIAA CREF Investment Management LLC. Company insiders that have bought Immune Design Corp stock in the last two years include Group L P Column, Lewis W Coleman and Stephen R Brady. View Insider Buying and Selling for Immune Design Corp.

How do I buy Immune Design Corp stock?

Shares of Immune Design Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Immune Design Corp stock cost?

One share of Immune Design Corp stock can currently be purchased for approximately $8.00.

Analyst Ratings

Consensus Ratings for Immune Design Corp (NASDAQ:IMDZ) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.00 (125.00% upside)

Analysts' Ratings History for Immune Design Corp (NASDAQ:IMDZ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Jefferies Group LLCReiterated RatingBuy$16.00 -> $18.00MediumView Rating Details
11/13/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
6/10/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
5/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Immune Design Corp (NASDAQ:IMDZ)
Earnings by Quarter for Immune Design Corp (NASDAQ:IMDZ)
Earnings History by Quarter for Immune Design Corp (NASDAQ:IMDZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017Q4 2016($0.57)($0.57)$1.34 million$2.06 millionViewListenView Earnings Details
11/9/2016Q316($0.71)($0.60)$1.73 million$8.20 millionViewListenView Earnings Details
8/9/2016Q2($0.68)($0.71)$1.50 million$1.13 millionViewN/AView Earnings Details
5/10/2016Q1($0.62)($0.61)$0.85 million$1.86 millionViewListenView Earnings Details
3/10/2016Q4($0.54)($0.60)$1.06 million$1.10 millionViewListenView Earnings Details
11/12/2015Q315($0.39)($0.37)$4.10 million$4.70 millionViewListenView Earnings Details
8/12/2015Q215($0.47)($0.54)$1.40 million$1.78 millionViewListenView Earnings Details
5/14/2015Q115($0.64)($0.56)$1.30 million$1.90 millionViewListenView Earnings Details
3/31/2015Q4 2014($0.68)($0.78)$0.78 million$1.80 millionViewListenView Earnings Details
11/12/2014Q3 14($0.36)($0.55)$0.20 million$3.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immune Design Corp (NASDAQ:IMDZ)
2017 EPS Consensus Estimate: ($2.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.61)($0.55)($0.58)
Q2 20172($0.65)($0.60)($0.63)
Q3 20172($0.62)($0.61)($0.62)
Q4 20172($0.65)($0.62)($0.64)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immune Design Corp (NASDAQ:IMDZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Immune Design Corp (NASDAQ:IMDZ)
Insider Ownership Percentage: 42.90%
Institutional Ownership Percentage: 53.07%
Insider Trades by Quarter for Immune Design Corp (NASDAQ:IMDZ)
Institutional Ownership by Quarter for Immune Design Corp (NASDAQ:IMDZ)
Insider Trades by Quarter for Immune Design Corp (NASDAQ:IMDZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Carlos V PayaInsiderSell3,940$5.35$21,079.00View SEC Filing  
1/4/2017Stephen R BradyEVPSell1,642$5.35$8,784.70View SEC Filing  
12/22/2016Lewis W ColemanDirectorSell10,000$6.20$62,000.00View SEC Filing  
12/16/2016Franklin M BergerDirectorSell50,000$6.55$327,500.00View SEC Filing  
9/20/2016Group L P ColumnMajor ShareholderBuy800,000$6.25$5,000,000.00View SEC Filing  
9/20/2016Lewis W ColemanDirectorBuy40,000$6.25$250,000.00View SEC Filing  
7/15/2016Stephen R BradyEVPBuy1,500$6.84$10,260.00View SEC Filing  
11/23/2015Wayne GombotzinsiderSell5,000$20.00$100,000.00View SEC Filing  
9/14/2015Wayne GombotzinsiderSell5,000$16.19$80,950.00View SEC Filing  
8/25/2015Lewis W ColemanDirectorBuy3,000$14.50$43,500.00View SEC Filing  
5/12/2015Proquest Investments Iv, L.P.Major ShareholderSell177,607$21.60$3,836,311.20View SEC Filing  
4/24/2015Proquest Investments Iv, L.P.Major ShareholderSell82,892$26.81$2,222,334.52View SEC Filing  
4/21/2015Franklin M BergerDirectorBuy25,000$26.50$662,500.00View SEC Filing  
4/21/2015Proquest Investments Iv, L.P.Major ShareholderSell45,820$26.51$1,214,688.20View SEC Filing  
4/16/2015Proquest Investments Iv, L.P.Major ShareholderSell53,914$28.23$1,521,992.22View SEC Filing  
4/7/2015Proquest Investments Iv, L.P.Major ShareholderSell7,495$26.72$200,266.40View SEC Filing  
3/25/2015Proquest Investments Iv, L.P.Major ShareholderSell18,156$27.64$501,831.84View SEC Filing  
3/23/2015Proquest Investments Iv, L.P.Major ShareholderSell44,464$27.52$1,223,649.28View SEC Filing  
3/18/2015Proquest Investments Iv, L.P.Major ShareholderSell50,309$26.09$1,312,561.81View SEC Filing  
3/12/2015Proquest Investments Iv, L.P.Major ShareholderSell129,342$24.94$3,225,789.48View SEC Filing  
3/9/2015Proquest Investments Iv, L.P.Major ShareholderSell39,446$25.45$1,003,900.70View SEC Filing  
7/29/2014Alta Partners Viii, L.P.Major ShareholderBuy299,559$12.00$3,594,708.00View SEC Filing  
7/29/2014Franklin M BergerDirectorBuy50,000$12.00$600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Immune Design Corp (NASDAQ:IMDZ)
Latest Headlines for Immune Design Corp (NASDAQ:IMDZ)
Source:
DateHeadline
americanbankingnews.com logoJefferies Group Analysts Reduce Earnings Estimates for Immune Design Corp (IMDZ)
www.americanbankingnews.com - May 22 at 7:06 AM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for Immune Design Corp (IMDZ)
www.americanbankingnews.com - May 20 at 7:40 AM
americanbankingnews.com logoFY2021 EPS Estimates for Immune Design Corp (IMDZ) Lifted by Jefferies Group
www.americanbankingnews.com - May 19 at 1:46 PM
finance.yahoo.com logoImmune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1
finance.yahoo.com - May 19 at 10:26 AM
americanbankingnews.com logoImmune Design Corp (IMDZ) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 12:30 PM
finance.yahoo.com logoInvestor Network: Immune Design Corp. to Host Earnings Call
finance.yahoo.com - May 17 at 5:51 PM
finance.yahoo.com logoImmune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 17 at 5:51 PM
finance.yahoo.com logoNew Clinical and Biomarker Data Validate Immune Design’s Lead Programs and Discovery Platforms
finance.yahoo.com - May 17 at 5:51 PM
businesswire.com logoAnalog Devices’ Versatile 50 Mbps RS-485 Transceiver Series Protects Communication in Harsh Environments
www.businesswire.com - May 11 at 11:32 PM
seekingalpha.com logoAsterias Biotherapeutics' (AST) CEO Stephen Cartt on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 11:32 PM
finance.yahoo.com logoETFs with exposure to Immune Design Corp. : May 11, 2017
finance.yahoo.com - May 11 at 6:30 PM
finance.yahoo.com logoImmune Design Corp. :IMDZ-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 1:23 PM
finance.yahoo.com logoImmune Design to Report First Quarter 2017 Financial Results & Provide Corporate Update
finance.yahoo.com - May 8 at 5:34 PM
finance.yahoo.com logoWhat's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?
finance.yahoo.com - May 8 at 5:34 PM
americanbankingnews.com logoImmune Design Corp (IMDZ) Expected to Announce Quarterly Sales of $1.78 Million
www.americanbankingnews.com - May 6 at 7:38 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Immune Design Corp (IMDZ) to Post -$0.62 EPS
www.americanbankingnews.com - May 4 at 11:40 PM
americanbankingnews.com logoImmune Design Corp (IMDZ) Given Media Sentiment Score of 0.18
www.americanbankingnews.com - May 4 at 10:17 AM
americanbankingnews.com logoPositive Press Coverage Somewhat Likely to Affect Immune Design Corp (IMDZ) Stock Price
www.americanbankingnews.com - May 1 at 12:20 PM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Unlikely to Affect Immune Design Corp (IMDZ) Stock Price
www.americanbankingnews.com - April 29 at 1:09 AM
americanbankingnews.com logoFavorable Media Coverage Unlikely to Affect Immune Design Corp (IMDZ) Stock Price
www.americanbankingnews.com - April 21 at 10:24 PM
finance.yahoo.com logoImmune Design Announces Presentations at the 2017 ASCO Annual Meeting
finance.yahoo.com - April 20 at 11:30 AM
americanbankingnews.com logoImmune Design Corp (IMDZ) Getting Positive News Coverage, Study Shows
www.americanbankingnews.com - April 17 at 1:23 PM
americanbankingnews.com logo$1.78 Million in Sales Expected for Immune Design Corp (IMDZ) This Quarter
www.americanbankingnews.com - April 15 at 7:56 AM
americanbankingnews.com logo Analysts Expect Immune Design Corp (IMDZ) Will Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - April 13 at 10:24 PM
americanbankingnews.com logoImmune Design Corp (IMDZ) Given Daily News Impact Rating of 0.15
www.americanbankingnews.com - April 13 at 7:21 PM
finance.yahoo.com logoWhy Is Immune Design (IMDZ) Up 27.9% Since the Last Earnings ... - Yahoo Finance
finance.yahoo.com - April 7 at 10:47 PM
finance.yahoo.com logoETFs with exposure to Immune Design Corp. : April 7, 2017
finance.yahoo.com - April 7 at 5:46 PM
americanbankingnews.com logoImmune Design Corp (IMDZ) Short Interest Update
www.americanbankingnews.com - April 7 at 5:31 PM
seekingalpha.com logoImmune Design: 2 Novel Orphan Oncology Candidates In Mid-Stage Trials
seekingalpha.com - April 7 at 10:25 AM
finance.yahoo.com logoWhy Is Immune Design (IMDZ) Up 27.9% Since the Last Earnings Report?
finance.yahoo.com - April 7 at 10:25 AM
americanbankingnews.com logo Immune Design Corp (IMDZ) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 3 at 11:37 PM
finance.yahoo.com logoIMMUNE DESIGN CORP. Financials
finance.yahoo.com - March 11 at 5:44 PM
finance.yahoo.com logoImmune Design reports 4Q loss - Yahoo Finance
finance.yahoo.com - March 8 at 6:39 PM
finance.yahoo.com logoImmune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
finance.yahoo.com - March 8 at 6:39 PM
americanbankingnews.com logoImmune Design Corp (IMDZ) Posts Earnings Results, Meets Expectations
www.americanbankingnews.com - March 8 at 2:21 PM
seekingalpha.com logoImmune Design's (IMDZ) CEO Carlos Paya on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 7 at 10:43 PM
us.rd.yahoo.com logoImmune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
us.rd.yahoo.com - March 7 at 5:37 PM
biz.yahoo.com logoIMMUNE DESIGN CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
us.rd.yahoo.com - March 7 at 5:37 PM
biz.yahoo.com logoQ4 2016 Immune Design Corp Earnings Release - After Market Close
biz.yahoo.com - March 7 at 11:04 AM
zacks.com logoWhat's in Store for Immune Design (IMDZ) in Q4 Earnings?
www.zacks.com - March 3 at 5:53 PM
nasdaq.com logoImmune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at
www.nasdaq.com - March 2 at 3:34 AM
us.rd.yahoo.com logo5:28 pm Immune Design to present new tumor eradication data for systemic plus intratumoral immunization that demonstrates tumor eradication with 'Prime-Pull' immunotherapy approach combining a ZVex vector and G100
us.rd.yahoo.com - March 1 at 10:33 PM
finance.yahoo.com logoImmune Design to Report Fourth Quarter and Year End 2016 Financial Results and Provide Corporate Update
finance.yahoo.com - March 1 at 5:33 PM
finance.yahoo.com logoImmune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at the American Association for Cancer Research (AACR) Annual Meeting 2017
finance.yahoo.com - March 1 at 5:33 PM
streetinsider.com logoImmune Design (IMDZ) Announces Receipt of Orphan Drug Designation for G100 Intratumoral Product Candidate
www.streetinsider.com - February 22 at 11:07 PM
finance.yahoo.com logoImmune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
finance.yahoo.com - February 22 at 12:40 PM
finance.yahoo.com logo8:03 am Immune Design confirms that the FDA has granted Orphan Drug Designation for its investigational intratumoral therapy, G100, for the treatment of follicular non-Hodgkin's lymphoma
finance.yahoo.com - February 22 at 12:40 PM
finance.yahoo.com logoImmune Design to Present at Upcoming Investor Conferences
finance.yahoo.com - February 18 at 10:57 AM
biz.yahoo.com logoIMMUNE DESIGN CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - January 10 at 6:49 PM
biz.yahoo.com logoIMMUNE DESIGN CORP. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - December 16 at 6:28 PM

Social

Chart

Immune Design Corp (IMDZ) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff